Sign inJoin waitlistJoin the waitlist

MP

Meredith Pelster

Physician · Verdi Oncology Tennessee PC

Credentials: · · · · · · ·

History

Verdi Oncology Tennessee PC
2024–Present

Hematology and Medical Oncology
University of Texas Health Science Center at Houston
2017–2020
Internal Medicine
McGaw Medical Center of Northwestern University
2014–2017
Pediatrics
Northwestern University
2014–2017
McGaw Medical Center of Northwestern University
2013–2014
Vanderbilt University School of Medicine
2009–2013
Hematology and Medical Oncology Fellow
University of Texas Health Science Center at Houston
Vanderbilt Univ.

Research

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
New England Journal of Medicine · 2023 · 448 citations
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Journal of Clinical Oncology · 2023 · 271 citations
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
Journal of Clinical Oncology · 2021 · First of 12 authors · 252 citations

AS
Alexander Spira
5 papers
MB
Minal Barve
5 papers
DS
David Sommerhalder
3 papers
RY
Rona Yaeger
3 papers
Tanios Bekaii-Saab
3 papers
WP
Wungki Park
3 papers
AS
Aditya Shetty
2 papers
AS
Alexander Starodub
2 papers
Aparna Hegde
2 papers
Benjamin Herzberg
2 papers
Brian Wolpin
2 papers
CF
Christos Fountzilas
2 papers

Clinical trials

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Study chair · Recruiting · Phase 2
SCRI Development Innovations, LLC
2025–2027
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Site PI · Recruiting · Phase 1
Compass Therapeutics
2026–2028